Details
Stereochemistry | RACEMIC |
Molecular Formula | C15H18N2.C3H6O3 |
Molecular Weight | 316.3948 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(O)C(O)=O.CC1=CC=C2N3CCNC4CCCC(C2=C1)=C34
InChI
InChIKey=PXRNCRKTECAYRB-UHFFFAOYSA-N
InChI=1S/C15H18N2.C3H6O3/c1-10-5-6-14-12(9-10)11-3-2-4-13-15(11)17(14)8-7-16-13;1-2(4)3(5)6/h5-6,9,13,16H,2-4,7-8H2,1H3;2,4H,1H3,(H,5,6)
Pirlindole is a selective and reversible inhibitor of monoamine oxidase (MAO) subtype A (MAO-A). It exerts an inhibitory effect on noradrenaline and 5-hydroxytryptamine reuptakes. It has no effect on the dopaminergic and cholinergic systems. It has only a low potential for amplifying tyramine and noradrenaline pressor effect, which makes one expect that it will not be at the basis of a ‘cheese effect’. Pirlindole was approved in some European and non-European countries for the treatment of depression. The antidepressant efficacy and safety of pirlindole have been demonstrated in a number of placebo- and active comparator-controlled studies and are supported by many years of clinical experience in the treatment of depression. The drug's efficacy and safety have also been demonstrated in the treatment of fibromyalgia syndrome. Pirlindole has a favorable tolerability profile, with no deleterious effect on cardiovascular dynamics. The effect of pirlindole on sensorimotor performance relevant to driving a motor vehicle is similar to that of placebo, as pirlindole appears to have an activating rather than a sedating antidepressant profile. Pirlindole prevented qualitative alteration (transformation) in the catalytic activity of membrane-bound type A monoamine oxidases (MAO-A), pathogenetically important for the development of the audiogenic seizures.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1951 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9564636 |
PubMed
Title | Date | PubMed |
---|---|---|
Comparative effects of dehydropirlindole and other compounds on rat brain monoamine oxidase type A. | 2002 Jan |
|
Computer visualisation of the active site of monoamine oxidase-A by means of selective inhibitors. | 2003 |
|
[Pirasidol in clinical practice]. | 2003 |
|
Monoamine oxidase A inhibitory potency and flavin perturbation are influenced by different aspects of pirlindole inhibitor structure. | 2003 Jun 1 |
|
[Pirasidol treatment of depression in elderly patients with somatic diseases]. | 2004 |
|
[Comparative analysis of antiarrhythmic and proarrhythmogenic effects of drugs for neuroleptanalgesia, ataralgesia, and antidepranalgesia in experimental acute myocardial infarction]. | 2006 Jul-Aug |
|
A meta-analysis of the efficacy of fibromyalgia treatment according to level of care. | 2008 |
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
515216
Created by
admin on Sat Dec 16 11:19:08 GMT 2023 , Edited by admin on Sat Dec 16 11:19:08 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
44121441
Created by
admin on Sat Dec 16 11:19:08 GMT 2023 , Edited by admin on Sat Dec 16 11:19:08 GMT 2023
|
PRIMARY | |||
|
DBSALT002871
Created by
admin on Sat Dec 16 11:19:08 GMT 2023 , Edited by admin on Sat Dec 16 11:19:08 GMT 2023
|
PRIMARY | |||
|
292039-20-4
Created by
admin on Sat Dec 16 11:19:08 GMT 2023 , Edited by admin on Sat Dec 16 11:19:08 GMT 2023
|
PRIMARY | |||
|
SUB15025MIG
Created by
admin on Sat Dec 16 11:19:08 GMT 2023 , Edited by admin on Sat Dec 16 11:19:08 GMT 2023
|
PRIMARY | |||
|
PRE19MC9Y9
Created by
admin on Sat Dec 16 11:19:08 GMT 2023 , Edited by admin on Sat Dec 16 11:19:08 GMT 2023
|
PRIMARY |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD